In termsof adjuvant therapy, the ongoing Phase III ALINA trial (NCT 03456076) isinvestigating the efficacy and safety of adjuvant alectinib versus chemotherapyin completely-resected, ALK-rearranged Stage IB-IIIA NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.